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Final oocyte maturation in GnRH antagonist co-treated IVF/ICSI cycles can be triggered with
HCG or a GnRH agonist. We conducted a systematic review and meta-analysis of randomized
controlled trials to evaluate the efﬁcacy and safety of the ﬁnal oocyte maturation trigger in
GnRH antagonist co-treated cycles. Outcome measures were ongoing pregnancy rate (OPR)
and ovarian hyperstimulation syndrome (OHSS) incidence. Searches: were conducted in
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In the last decade, GnRH antagonist has been introduced to
the market to be used for pituitary desensitization in IVF/ICSI
treatment cycles. GnRH antagonist shown to be an effective
alternative to the standard long GnRH agonist protocols [1].
There is an ongoing debate over the optimal agent that can
trigger ﬁnal oocyte maturation in GnRH antagonist, leading
to higher IVF success rate without increasing the risk of ovar-
ian hyperstimulation syndrome (OHSS).
Due to the speciﬁcmode of action ofGnRHantagonist, quick
and reversible response, GnRHagonist as a mid-cycle bolus dose
varying from0.1up to0.5 andHCGadministration couldbe used
to induce ﬁnal oocyte maturation triggering. GnRH agonist
induces endogenous LH and FSH surges which might simulate
the natural mid-cycle LH surge. The serum LH and FSH levels
rise after 4 and 12 h, respectively, and are elevated for 24–36 h.
The amplitude of the surges is similar to those seen in the normal
menstrual cycle but, in contrast to the natural cycle, the LH surge
consists of two phases. These are a short ascending limb (>4 h)
and a long descending limb (>20 h). Thus, ﬁnal oocyte matura-
tion trigger withGnRH agonist results in corpus luteum deﬁcien-
cy and a defective luteal phase (Segal and Casper, 1992) and is
associated with very low ongoing pregnancy rate [2]. For this rea-
son, several schemes of luteal support have been used to increase
the chance of pregnancy [3–5], although there is no agreement yet
regarding which is the optimal one.
Human chorionic gonadotropin (hCG), in addition to its
well-known endocrine effect on the corpus luteum, it is the tra-
ditional ﬁnal oocyte maturation trigger in GnRH agonist co-
treated cycles for more than 3 decades [1]. Some studies have
suggested a negative impact of HCG on endometrial [6–8]
and embryo quality [9,10]. In addition, the sustained
luteotrophic effect of HCG is associated with increased chances
of ovarian hyperstimulation syndrome (OHSS) [11]. OHSS in
its moderate and severe forms can cause signiﬁcant morbidity
and can be fatal in its critical stage. The incidence of severe
OHSS is low and in the range of 0.5–2% of all IVF cycles [12].
Currently, there is no agreement on the optimal agent for
inducing ﬁnal oocyte maturation triggering in GnRH antago-
nist co-treated cycles yet. The purpose of our review was to
evaluate and determine the efﬁcacy and safety of both triggers
in GnRH antagonist co-treated IVF/ICSI cycles.
Methodology
Search strategy for identiﬁcation of studies
The following electronic databases were searched: MEDLINE,
EMBASE, Science Direct, Cochrane Central Register of
Publications excluded 
(n= 82)
RCTs included in meta-analysis (n= 19)
RCTs withdrawn (n=0)
RCTs with usable information (n=19)
GnRH agonist vs. HCG (n= 15)
Timing of HCG administration (n= 2)
Potentially relevant publications
identified and screened for retrieval 
(n= 101)
Fig. 1 Flow diagram for meta-analysis. Identiﬁcation and
selection of publications.
GnRH agonist trigger 343Controlled Trials (CENTRAL) and Web of Science. National
Research Register (NRR) a register of ongoing trials and the
Medical Research Council’s Clinical Trials Register a search
strategy were carried out based on the following terms: GnRH
antagonist, ﬁnal oocyte maturation triggering, HCG, GnRH
agonist, AND ovarian hyperstimulation syndrome chorionic
‘‘or ‘‘OHSS ‘‘AND’’ IVF/ICSI/ART AND ‘‘randomized con-
trolled trial(s)’’ OR ‘‘randomized controlled trial(s)’’. Further-
more, we examined the reference lists of all known primary
studies, review articles, citation lists of relevant publications,
abstracts of major scientiﬁc meetings (e.g. ESHRE and
ASRM) and included studies to identify additional relevant
citations. Finally, the review authors sought ongoing and
unpublished trials by contacting experts in the ﬁeld. In addi-
tion, references from all identiﬁed articles were checked, and
a hand search of the abstracts from the annual meetings of
the American Society for Reproductive Medicine and the
European Society for Human Reproduction and Embryology
was performed. If necessary, additional information was
sought from the authors. The search was not restricted by lan-
guage. The searches were conducted independently by M.Y,
M.H and M. van W.
Study selection and data extraction
Studies were selected if the target population was infertile cou-
ples undergoing GnRH antagonist co-treated – IVF/ICSI
treatment cycles. The therapeutic interventions were GnRH
agonist or HCG for ﬁnal oocyte maturation triggering. Studies
had to be of randomized design. The primary outcome mea-
sure of interest was ongoing pregnancy rate per randomized
woman.
Studies were selected in a two-stage process. First, the titles
and abstracts from the electronic searches were scrutinized by
two reviewers independently (M.Y and H.A) and full manu-
scripts of all citations that were likely to meet the predeﬁned
selection criteria were obtained. Secondly, ﬁnal inclusion or
exclusion decisions were made on examination of the full
manuscripts. The selected studies were assessed for method-
ological quality by using the components of study design that
are related to internal validity (Juni et al., 2001). Information
on the adequacy of randomization, concealment and blinding
was extracted. When needed the reviewers wrote the authors
and tried to get hold of extra information and the raw data.
From each study, outcome data were extracted in 2 · 2 tables.
Deﬁnition of outcome measures
The outcomes we planned to assess in our analysis were ongo-
ing pregnancy rate and OHSS incidence and number of
retrieved follicles were calculated based on the number of
patients randomized in all studies even if some patients were
excluded or dropped out after randomization.
Statistical analysis
Dichotomous outcomes were expressed as an odds ratio (OR)
with 95% CI using a ﬁxed effects model. Continuous outcomes
were expressed as a mean difference (MD) with 95% CI. All
statistical analyses were performed using RevMan 5.0
(Cochrane Collaboration, Oxford, UK).Results
The search strategy yielded 101 publications related to the
topic. 82 publications were excluded as they did not fulﬁl the
selection criteria (Fig. 1). Our review and meta-analysis includ-
ed all randomized controlled studies that evaluated ﬁnal
oocyte maturation triggering in GnRH antagonist co-treated
cycles. 15 randomized controlled studies (n= 2259) evaluated
GnRH agonist trigger in GnRH antagonist co-treated cycles
(Table 1). 15 studies compared HCG with GnRH agonists,
11 RCTs in fresh autologous cycles and 4 RCTs in donor reci-
pient cycles [4,5,13–21,3,22–24]. One study evaluated the lower
effective dose of HCG and 3 studies evaluated the effect of
delaying or advancement of HCG administration and one
study compared u HCG with rec HCG. Nine studies were ran-
domized controlled single-centre studies [3,4,13,14,17,19,22–
24]. Four studies were two-centre studies [15,18,20, and 21].
One study was a three-centre study [5] and one study was a
six-centre study [16]. Ten studies performed a sample size cal-
culation of the number of patients needed to achieve the pri-
mary outcome [4,5,15,18,20,14,17,21,22,24]. There was no
sample size calculation in three studies [13,16,3]; in two studies
it was unknown [19,23]. Two studies failed to achieve the
intended sample size [18,20]. Only three studies performed
blinding for the assessors [22–24]. Two studies reported blind-
ing unclearly [15,3]. Other studies reported no blinding. How-
ever, blinding of assessors would seem irrelevant given the
objectivity of the outcomes. Therefore, all studies were at high
risk of bias in regard to blinding. All included studies are pub-
lished in peer reviewed journals as a full text. Although, there
was heterogeneity between the most of the included studies as
regards the inclusion and exclusion criteria, primary outcomes
and luteal phase support and most of them were properly ran-
domized using computer generated list (see Fig. 2).
 Ongoing pregnancy rate: There was a statistically sig-
niﬁcant difference against the GnRH agonist with an
OPR in fresh autologous cycles (n= 1024) of, OR: 0.69;
Table 1 Characteristics of randomized trials included in the systematic review and meta-analysis.
I-Studies comparing HCG with GnRH agonist in fresh ET-GnRH antagonist co-treated cycles
Trial Participants Interventions Outcomes Study design
Randomized controlled studies with
traditional luteal phase support
1. Fauser (2002) 57 women for IVF/ICSI. Age (18–39 years),
regular menstrual cycle (24–35 d) and BMI:
18–29 kg/m2
Ovarian stimulation: adjustable dose of 150–
225 IU r FSH+ 0.25 mg ganirelix.
Intervention: 0.2 mg triptorelin versus 0.5 mg
leuprorelin versus 10,000 IU hCG. Luteal
phase support: progesterone 50 mg
FSH, LH, E2, hCG, and P in the luteal
phase, FSH consumption; duration of
FSH treatment, number of oocytes, MII,
FR, IR, OPR
RCT, open label, three-arm,
6 international centre study
2. Beckers (2003) 40 patients for IVF/ICSI. Age 6 38 years,
regular menstrual cycle, both ovaries present,
absence of uterine abnormalities, BMI: 18–
29 kg/m2, no history of poor ovarian response
or moderate or severe OHSS
Ovarian stimulation: ﬁxed dose of 150 IU r-
hFSH+ 1 mg daily sc antide. Intervention:
0.2 mg sc triptorelin versus 250 lg/ml sc r-
hCG versus 1 mg sc r-LH. Luteal phase
support: none
LH (day of oocyte retrieval), day of
progesterone maximal level, day of
decrease of P. duration follicular phase,
number of oocytes retrieved, OPR
RCT, three arms, two-centre
study
3. Kolibianakis (2005) 106 women for IVF/ICSI. Age 6 39 years,
normal day-3 serum FSH levels, 63 previous
assisted reproduction treatment (ART)
attempts, BMI (18–29 kg/m2), regular
menstrual cycles, no PCOS or previous poor
response to ovarian stimulation, both ovaries
present
Ovarian stimulation: ﬁxed dose of 200 IU r
FSH+ 0.25 mg orgalutran. Intervention:
0.2 mg triptorelin versus 10 000 IU of HCG.
luteal phase support: 600 mg/day natural
micronized progesterone plus daily 2 · 2 mg
oral estradiol
FR, OPR.IR, days of stimulation, total
units of r FSH, number of COCs follicles
ofP11 mm on the day of triggering,
number of follicles ofP17 mm, MII%
oocytes, number of 2PN oocytes, number
of embryos transferred, E2 (pg/ml),
progesterone (ng/l)
RCT, two armed, 1:1
randomizations ratio, open
label; parallel design; two-
centre study
4. Babayof (2006) 28 women with PCOS for IVF Ovarian stimulation: adjustable dose of
225 IU sc r FSH+ 0.25 mg sc cetrotide.
Intervention: 0.2 mg decapeptyl versus 250 lg
r HCG. Luteal phase support: 50 mg/day of
progesterone Im ± 4 mg/day E2 PO
Serum levels of inhibin A, VEGF, TNFa,
E2, progesterone and incidence of OHSS,
ovarian size and pelvic ﬂuid
accumulation, LBR,OPR, MII% oocytes
RCT, single-centre study
Randomized controlled studies with modiﬁed
luteal phase support
(a) GnRH agonist plus low dose of HCG
5. Humaidan (2005) 122 normo-gonadotrophic women for IVF or
ICSI. Age  25–40 years FSH and LH,
12 IU/l, menstrual cycles between 25 and
34 days, BMI 18–30 kg/m2, both ovaries
present, absence of uterine abnormalities
Ovarian stimulation: adjusted dose of 150 or
200 IU r FSH on cd 2 + 0.25 mg ganirelix.
Intervention: 0.5 mg buserelin sc versus 10
000 IU hCG sc. Luteal phase support: 90 mg/
day P, vaginally + estradiol 4 mg/day
Positive hCG per ET.CPR. Early
pregnancy loss, rate of embryo transfer.
Numbers of embryos transferred, IR,
oocytes retrieved, MII% oocytes
RCT, open label, two-centre
study
6. Humaidan (2006) 45 normo-gonadotrophic women for IVF/
IGSI, age 25–40 years, base-line FSH and
LH<12 IU/1, menstrual cycles between 25
and 34 days, BMI 18–30 kg/m2, both ovaries
present, absence of uterine abnormalities.
Each patient contributed with only one cycle
Ovarian stimulation: adjusted dose of 150–
200 IU r-hFSH on cd 2+ 0.25 mg ganirelix.
Intervention: 0.5 mg buserelin sc plus HGG
1500 IU i.m. 12 h versus 0.5 mg buserelin sc
1500 IU i.m. 35 h after the buserelin injection
versus 10,000 IU of HGG sc. Luteal phase
support: 90 mg/day P + 4 mg/day estradiol
Serum P, inhibin A concentration, dose of
FSH, duration of FSH stimulation,
number of oocytes, number of embryos,
rate of transfer, number of embryos
transferred, CPR, early pregnancy loss
RCT, open label, single-
centre study
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7. Humaidan (2010) 302 normo-gonadotrophic IVF/ICSI patients,
age 25–40 yrs, BMI 18–30 kg/m2, basal
FSH<12 IU/L, menstrual cycle 25–34 days,
both ovaries present, absence of uterine
abnormalities. Each patient contributed with
only one cycle
Ovarian stimulation: adjustable dose of
150–200 IU r FSH+ 0.25 mg ganirelix.
Intervention: 0.5 mg buserelin sc plus
1500 IU hCG i.m 35 h after triggering of
ovulation versus 10 000 IU of hCG.
Luteal phase support: 90 mg/day P + E2
4 mg/day
Primary outcom : reduction of the high
early pregnancy ss rate. Secondary
outcomes: MII o cytes retrieved, OHSS
incidence, ongoi pregnancy rate
RCT, three-centre study
8. Schacter (2008) 221 infertile patients needing IVF-ET who
had failed at least one previous IVF-ET cycle
on GnRH agonist long protocol. Exclusion
criteria: patients whose previous cycle was
characterized by lack of oocytes aspirated.
BMI 18–30 kg/m2
Ovarian stimulation: adjustable dose
HMG+ 0.25 mg cetrorelix. Intervention:
0.2 mg triptorelin sc plus 1500 IU hCG
i.m versus 10,000 IU of hCG. Luteal
phase support: vaginal P only (400 mg/d
Utrogestan)
OPR, IR RCT, single centre study
Randomized controlled studies with modiﬁed luteal phase support
(b) GnRH agonist plus intense luteal phase support
9. Pirard (2006) 30 infertile patients for IVF/ICSI Ovarian stimulation: OCP + 150–300 IU
hMG/FSH on cd 3 + 0.25 mg
orgalutran. Intervention and luteal phase
support: (group A) 10,000 IU
hCG+ 200 mg micronized progesterone
three times daily, (group B) 200 lg
intranasal (IN) buserelin followed by
100 lg IN buserelin/2 days; (group C),
200 lg IN buserelin followed by 100 lg
IN buserelin/day, (group D) 200 lg IN
buserelin followed by 100 lg IN buserelin
twice a day (group E) 200 lg IN buserelin
followed by 100 lg IN buserelin three
times a day
Luteal phase du tion in non-pregnant
patients (days), n mber of patients with a
luteal phase >10 ays, positive
pregnancy test, c nical pregnancy rate,
OHSS incidence etrieved oocytes,
retrieved oocytes ollicles >10 mm
cleaved embryos cleaved embryos/
retrieved oocytes transferred embryos
RCT, open, parallel group,
pilot, single-centre trial
10. Papinokolaou (2011) 35 infertile women, inclusion criteria were: [1]
age <36 years, [2] elective single embryo
transfer on day 5, and [3] basal FSH< 12
mIU/mL. Exclusion criteria were: [1]
polycystic ovary syndrome (PCOS); [2] use of
testicular sperm; and [3] endometriosis stages
III and IV
Ovarian stimulation: ﬁxed dose 187.5 IU
of rec FSH starting on day 2 of the cycle
with co-administration of GnRH-
antagonist, 0.25 mg cetrorelix
Intervention: 250 mg of recombinant
hCG versus 0.2 mg of triptorelin Luteal
phase support: 600 mg micronized P
vaginally plus six doses every other day of
300 IU recombinant LH (Luveris, Merck-
Serono) starting on the day of oocyte
retrieval up to day 10 after oocyte
retrieval
Implantation rat , clinical pregnancy,
OHSS incidence
RCT, single blind study
(continued on next page)
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Table 1 (continued)
I-Studies comparing HCG with GnRH agonist in fresh ET-GnRH antagonist co-treated cycles
Trial Participants Interventions Outcomes Study design
11. Engmann (2008) 66 infertile women, age 20–39 years,
FSH 6 10.0 IU/L undergoing their ﬁrst
cycle of IVF with either PCOS or PCOM
or undergoing a subsequent cycle with a
history of high response in a previous IVF
cycle
Ovarian stimulation: OCP + long GnRH
agonist + r FSH (control group) or
0.25 mg ganirelix. Intervention: 1.0 mg
leuprolide versus 3300–10,000 IU of
hCG. Luteal phase support: 50 mg IM
P+ 0.1 mg E2 patches
OHSS, IR, number of oocytes retrieved,
MII %, FR, midluteal phase mean
ovarian volume (MOV), CPR, OPR
RCT, single centre
II-Studies comparing HCG with GnRH agonist in donor-ET-GnRH antagonist co-treated cycles
12. Acevado (2006) 60 oocyte donors. Age 18–35 years, with
normal menstrual cycle: no PCOS,
endometriosis, hydrosalpinges, or severe
male factor. 98 recipient age range 34–
47 years received oocyte but only 60
patients who are analysed
Ovarian stimulation: ﬁxed dose of 150 IU
r FSH on cd 3/4 f + 0.25 mg/day sc
orgalutran + 75 IU/day of LH.
Intervention: 0.2 mg, sc triptorelin versus
250 lg/mL sc r Hcg. Luteal phase support
(recipients): E2 plus 600 mg /day natural
progesterone
Donors Primary outcomes: OHSS.
Secondary outcomes: FSH and LH
units(IU), GnRH antagonist ampoules,
E2 levels, follicles number on day ﬁve of
COH and HCG day. Recipients.
Pregnancy rates, implantation rates
RCT, single-centre, donor-
recipient study
13. Melo (2007) 70 oocyte donors, age 18–34 years,
regular menstrual cycles, no family
history of hereditary or chromosomal
diseases, normal karyotype, BMI 18–
29 kg/m2, and negative screening for
sexually transmitted diseases. PCOS was
excluded. 96 recipients women with
menopause. Exclusion criteria: cases with
uterine pathology, implantation failure
and recurrent miscarriage
Oocyte donors. Ovarian stimulation:
OCP + adjustable dose of 225 IU r
FSH+ 0.25 mg cetrotide. Intervention:
0.2 mg triptorelin sc versus 250 lg of
rhCG sc. Luteal phase support
(recipients): 800 mg/day of micronized
intravaginal progesterone
Donors: oocytes retrieved, proportion of
MII oocytes, fertilization rate, cleavage
rate, top quality embryos, N. embryos
transferred, OHSS rate. Recipients:
implantation rate, clinical pregnancy rate,
multiple pregnancy rate, miscarriage rate
RCT, assessor-blinded,
parallel groups, single-centre
study
15. Galindo (2009) 257 oocyte donors, age 18–35 years old,
BMI < 30 kg/m2 regular (26–35 days)
menstrual cycles. Patients with a previous
history of low response to ovarian
stimulation, PCO or using OCP. were
excluded
Ovarian stimulation: 225 IU of r FSH on
cd 2 + 0.25 mg/day cetrotide.
Intervention: 0.2 mg triptorelin sc versus
250 lg r hCG. Luteal phase support:
800 mg of micronized vaginal
progesterone daily
Donors: stimulation duration, FSH dose,
ﬁnal E2 level and follicular count, FR,
OHSS incidence. recipients: CPR, LBR,
IR
RCT, open label, single-
centre study
16. Sismanglou (2009) Eighty-eight stimulation cycles in 44 egg
donors
Ovarian stimulation: r FSH or
HMG+GnRH antagonist.
Intervention: 0.15 mg leuprolide sc versus
3000–10,000 IU hCG. Luteal phase
support: 600 mg of micronized vaginal
progesterone daily
MII, oocyte retrieved, implantation and
pregnancy rate and OHSS
RCT, cross-over, single
centre study
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Fig. 2 Forest plot of odds rations and 95% CI of pooled trial comparing GnRH agonist versus HCG administration according to the
ongoing pregnancy rate (a) and incidence of OHSS per randomized women (b).
GnRH agonist trigger 34795% CI: 0.52–0.93. In oocyte-donor cycles (n= 342) there
was no evidence of a difference (OR: 0.91; 95% CI: 0.59–
1.40).
 Ovarian hyperstimulation incidence (OHSS): There was a
statistically signiﬁcant difference in favour of GnRH ago-
nist regarding the incidence of OHSS in fresh autologous
(OR: 0.06; 95% CI: 0.01–0.33 and donor cycles respectively
(OR: 0.06; 95% CI: 0.01–0.27).
Discussion
Our review has shown that HCG administration seems to be
more effective trigger for ﬁnal oocyte maturation in GnRH
antagonist co-treated IVF/ICSI treatment cycles than GnRH
agonist. This is evidenced by the higher ongoing pregnancy rate
we found in the HCG group (15 RCTs, OR: 0.75, 9R% CI:
0.59–0.96). Conversely, GnRH agonists seem to be safer than
traditional HCG due to the associated low risk of OHSS (10
RCTs, OR: 0.06, 9R% CI: 0.02–0.19). However, the majority
of studies evaluated GnRH agonist was conducted in normo-re-
sponder’s patients with normal risk to develop OHSS.Some investigators suggest that by administrating GnRH
agonists rather than HCG, for ﬁnal oocyte maturation trigger-
ing, the risk of OHSS is reduced without compromising preg-
nancy rates [19–21,3]. Surprisingly, out of 15 studies who
evaluated GnRH agonist as a trigger, only 2 small RCTs
evaluated agonists in women with PCOS at high risk to devel-
op OHSS, meanwhile other studies included normo-responders
women at a normal risk for OHSS. First study shown a non-
signiﬁcant reduction in the incidence of OHSS as the number
of participants was too small and the primary outcome was
inhibin A levels on the day of embryo transfer [14]. Second
study, included only 66 infertile PCOS women, the incidence
of OHSS was signiﬁcantly reduced with comparable implanta-
tion rates, however, the study was not powered to evaluate
pregnancy rate [16]. Marked luteolysis and luteal phase defect
have been suggested to be the explanation of the associated
lower pregnancy rate. Although, many luteal phase support
modiﬁcations have been tried, in order to be as efﬁcient trigger
as HCG, such as co-administration of low dose of HCG
(1500 IU) [25] or multiple doses of GnRH agonist in the luteal
phase [24] or multiple injections of rec LH [23] and intense
luteal phase support with high doses of progesterone plus
348 M.A.F. Youssef et al.estradiol patches [16] to overcome the insufﬁciency of luteal
phase in GnRH agonist group, the pregnancy rate was not
improved [2]. Recently, it has been suggested that GnRH ago-
nist trigger with cryopreservation followed by later embryos
transfer is more safe and effective [26]. This strategy is support-
ed by the recently published study showing that the clinical
pregnancy rate was signiﬁcantly greater in the cryopreserva-
tion group than the fresh transfer group which is attributed
to be due to superior endometrial receptivity in the cryopreser-
vation group than the fresh group. These results strongly sug-
gest impaired endometrial receptivity in fresh ET cycles after
ovarian stimulation, when compared with FET cycles with
artiﬁcial endometrial preparation. Impaired endometrial
receptivity apparently accounted for most implantation fail-
ures in the fresh group [26].
The strengths of this review include comprehensive system-
atic searching for eligible studies, rigid inclusion criteria for
RCTs, and data extraction and analysis by two independent
investigators. Furthermore, the possibility of publication bias
was minimized by including both published and unpublished
studies. However, as with any review, we cannot guarantee
that we found all eligible studies.
Conclusions
The evidence suggests that GnRH agonists as a ﬁnal oocyte
maturation trigger in fresh autologous cycles should not be
used routinely due to its association with a signiﬁcantly lower
live birth rate, lower ongoing pregnancy rate and higher rate of
early miscarriage. The only indication for GnRH agonist use
as oocyte maturation trigger is in women who donate oocytes
to recipients or in women who wish to freeze their eggs for
later use in the context of fertility preservation.
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